We report the results of a consensus conference on the diagnosis of multiple system atrophy (MSA). We describe the clinical features of the disease, which indude four domains: autonomic failure/urinary dysfunction, parkiusonism and cerebellar ataxia, and corticospinal dysfunction. We set criteria to define the relative importance of these features. The diagnosis of possible MSA requires one criterion plus two features from separate domains. The diagnosis of probable MSA requires the criterion for autonomic failure/urinary dysfimction plus poor levodopa responsive parkiusonism or cerebella* ataxia. The diagnosis of definite MSA requires pathological confirmation.
The parkinsonian features include bradykinesia with rigidity, postural instability, hypokinetic speech, and often tremor, usually with a poor or unsustained response to chronic levodopa therapy. The cerebellar dysfunction consists of ataxia of gait, limb movements and speech, and disorders of extraocular movements [7] . Autonomic insufficiency results in orthostatic hypotension, often with an inadequate heart rate response to standing, male erectile dysfunction (MED), constipation, and decreased sweating [8, 9] . Urinary symptoms include urgency, frequency, nocturia, incomplete bladder emptying, and incontinence [10] . The diagnosis of MSA requires primarily clinical assessment; however, a number of laboratory tests may help to support the diagnosis.
The neuropathological changes consist of a high density of glial cytoplasmic inclusions (GCIs) in association with degenerative changes in some or all of the following structures: putamen, caudate nucleus, globus pallidus, substantia nigra, locus ceruleus, inferior olives, pontine nuclei, cerebellar Purkinje cells, autonomic nuclei of the brainstem, and the intermediolateral cell columns and Onus nucleus in the spinal cord [11, 12] . GCIs are ubiquitin-, tan-and a-synuclein-positive oligodendroglial inclusions [12] .
Some efforts have been made to establish diagnostic criteria [4] , but no consistent detailed guidelines have been developed. Accordingly, a consensus conference was convened on April 23 and 24, 1998 in Minneapolis, Minnesota, cosponsored by the American Autonomic Society and the American Academy of Neurology. The goal of the conference was to develop guidelines for the diagnosis of MSA. We achieved consensus on the items listed below and shown in Tables  1, 2 , and 3. These guidelines have not yet been validated, and will almost certainly require further modification in the light of future experience.
Clinical domains

Autonomic and urinary dysfunction
Orthostatic hypotension (OH) may indicate autonomic failure and can be asymptomatic or symptomatic. When symptomatic, it typically occurs after the onset of MED and urinary symptoms. Symptoms of OH result from cerebral hypoperfusion, and syncope may occur. The consensus conference determined that the clinical diagnosis of probable MSA requires a reduction of systolic blood pressure by at least 30 mm Hg or of diastolic blood pressure by at least 15 mm Hg within 3 minutes of standing from the recumbent * Please see "Conference Participants" section at the end of this article for a full listing of author affiliations. position. Frequently this is accompanied by an inadequate increase in heart rate (less than 10 beats per minute). We note that this is a more pronounced degree of OH than established previously [4] . MED appears early and affects virtually all male patients with MSA, but the symptom has Table 1 *In practice, MSA is most frequently confused with Parkinson's disease or progressive supranuclear palsy (PSP) [25] . Mild limitation of upward gaze alone is nonspecific, whereas a prominent (>50%) limitation of upward gaze or any limitation of downward gaze suggests PSP, Before the onset of vertical gaze limitation, a clinically obvious slowing of voluntary vertical saccades is usually easily detectable in PSP and assists in the early differentiation of these two disorders [26] .
low specificity. Urinary frequency, urgency, incontinence, or incomplete bladder emptying also occur early and commonly.
Parkinsonism
The majority of MSA patients develop parkinsonian features at some stage of the disorder. All these patients have bradykinesia; rigidity, postural instability, and tremor also often occur. The tremor is usually irregular and postural, often incorporating myoclonus. A classical pill-rolling parkinsonian rest tremor is uncommon. The parkinsonism in MSA can be asymmetric. The dysarthria is mainly hypokinetic, often mixed with other components [ 13] . The parkinsonian features usually respond poorly to chronic levodopa therapy; however, up to 30% of patients show a clinically significant response to levodopa therapy at some time in the course, but the response is usually sustained for less than five years [5, 14, 15] . These are the most challenging patients for accurate diagnosis.
Cerebellar dysfunction
Ataxia of gait, the most common cerebellar feature of MSA, often occurs accompanied by dysarthria, limb ataxia, and sometimes gaze-evoked nystagmus and ocular dysmetria. A common finding is saccadic pursuit movements. The dysarthria in patients with predominantly cerebellar dysfunction is mainly ataxic, often mixed with other components [13] .
Corticospinal dysfunction
Extensor plantar responses with hyperreflexia occur in about 50% of MSA patients. Corticospinal signs can contribute to the diagnosis, but are less important than abnormalities in the other domains.
Diagnosis of MSA
Response to levodopa
Levodopa responsiveness should be tested by administering escalating doses (with a peripheral decarboxylase inhibitor) over a 3-month period up to at least I g per day (if necessary and if tolerated). A positive response is defined as clinically significant improvement. This should be demonstrated by objective evidence such as an improvement of 30% or more on part III (motor examination) of the Unified Parkinson's Disease Rating Scale [16] .
Laboratory investigations
Autonomic function tests, sphincter electromyography (EMG), and neuroimaging may be used to support the diagnosis, and neuroimaging is helpful in excluding other conditions. The abnormalities described below have been defined principally in clinically well-established cases rather than in the early stages of the disease. In the early stages, the tests may give equivocal results. We consider it premature to incorporate laboratory results into the entirely clinical guidelines that we established, but envision the future development of "Laboratory Supported" diagnostic categories. Assessment of autonomic function can be assisted by a comprehensive battery that evaluates the distribution and severity of sudomotor, cardiovagal, and sympathetic adrenergic deficits [17, 18] . Autonomic function tests may help separate MSA from Parkinson's disease and from idiopathic cerebellar degenerations [8] .
Sphincter EMG can be useful in the diagnosis of MSA. Analysis of individual motor unit potentials recorded from the external anal sphincter usually shows changes indicating chronic reinnervation, with markedly prolonged motor units [10, 19] .
Magnetic resonance imaging (MRI) can assist the evaluation by detecting abnormalities ofstriatum, cerebellum, and brainstem, but can be normal in up to 20% of cases [20] . Striatal abnormalities may include putaminal atrophy, slitlike signal change at the posterolateral putaminal margin, and hypointensity of the putamen relative to the globus pallidus [21] . Infratentorial abnormalities include cerebellar and pontine atrophy, and signal change in the pons and middle cerebellar peduncles [22] . Studies are in progress to evaluate the utility of magnetic resonance spectroscopy, positron emission tomography, and single photon emission tomography.
Diagnostic categories
We established three diagnostic categories reflecting differing levels of certainty: definite, probable, and possible. The diagnosis of definite MSA can only be made after neuropathological examination of the central nervous system revealing the characteristic density and distribution of GCIs and degenerative changes outlined above. The diagnosis of probable or possible MSA can be made using different combinations of clinical domains, criteria, and features, as indicated in Tables  1 and 2 . Exclusion criteria are shown in Table 3 .
Terminology
MSA is a distinct clinicopathological entity. The term should not be used to describe other neurodegenerative diseases affecting multiple systems. The use of confusing terms such as "multisystem degeneration" for MSA is inappropriate and now should be discouraged. We recommend designating patients as having MSA-P if parkinsonian features predominate or MSA-C if cerebellar features predominate [23, 24] . These terms are intended to replace the striatonigral degeneration (SND) and sporadic olivopontocerebellar atrophy (sOPCA) types of MSA, respectively. The term Shy Drager syndrome has been widely misused, and is no longer useful.
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